{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:17:17Z","timestamp":1793207837434,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000185","name":"United States Department of Defense | Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","award":["HR0011-20-2-0029"],"award-info":[{"award-number":["HR0011-20-2-0029"]}],"id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R37DA045657"],"award-info":[{"award-number":["R37DA045657"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-57956-7","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T19:01:37Z","timestamp":1742410897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The structural diversity of psychedelic drug actions revealed"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1309-3069","authenticated-orcid":false,"given":"Ryan H.","family":"Gumpper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-3326","authenticated-orcid":false,"given":"Manish K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuglae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"DiBerto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-4767","authenticated-orcid":false,"given":"Brian E.","family":"Krumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Kapolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5327-832X","authenticated-orcid":false,"given":"H. \u00dcmit","family":"Kaniskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2384","authenticated-orcid":false,"given":"Jonathan F.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-6520","authenticated-orcid":false,"given":"Bryan L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"57956_CR1","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"key":"57956_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"57956_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"57956_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399\u2013408 (2018).","journal-title":"Psychopharmacology"},{"key":"57956_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","volume":"10","author":"JJ Fuentes","year":"2019","unstructured":"Fuentes, J. J., Fonseca, F., Elices, M., Farr\u00e9, M. & Torrens, M. Therapeutic use of LSD in psychiatry: A systematicreview of randomized-controlled clinical trials. Front. Psychiatry 10, 943 (2019).","journal-title":"Front. Psychiatry"},{"key":"57956_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","volume":"4","author":"G Agin-Liebes","year":"2021","unstructured":"Agin-Liebes, G. et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol. Transl. Sci. 4, 543\u2013552 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"57956_CR7","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","volume":"48","author":"L Ley","year":"2023","unstructured":"Ley, L. et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology 48, 1659\u20131667 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"57956_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu, A. et al. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J. Psychopharmacol. 33, 1088\u20131101 (2019).","journal-title":"J. Psychopharmacol."},{"key":"57956_CR9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0333102410363490","volume":"30","author":"M Karst","year":"2010","unstructured":"Karst, M., Halpern, J. H., Bernateck, M. & Passie, T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 30, 1140\u20131144 (2010).","journal-title":"Cephalalgia"},{"key":"57956_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","volume":"21","author":"TD McClure-Begley","year":"2022","unstructured":"McClure-Begley, T. D. & Roth, B. L. The promises and perils of psychedelic pharmacology for psychiatry. Nat. Rev. Drug Discov. 21, 463\u2013473 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"57956_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols, D. E. Psychedelics. Pharmacol. Rev. 68, 264\u2013355 (2016).","journal-title":"Pharmacol. Rev."},{"key":"57956_CR12","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon, R. A., Titeler, M. & McKenney, J. D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35, 2505\u20132511 (1984).","journal-title":"Life Sci."},{"key":"57956_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso, J. et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53, 439\u2013452 (2007).","journal-title":"Neuron"},{"key":"57956_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00176847","volume":"94","author":"M Titeler","year":"1988","unstructured":"Titeler, M., Lyon, R. A. & Glennon, R. A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94, 213\u2013216 (1988).","journal-title":"Psychopharmacology"},{"key":"57956_CR15","doi-asserted-by":"publisher","unstructured":"Preller, K. H. et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. ELife 7, https:\/\/doi.org\/10.7554\/elife.35082 (2018).","DOI":"10.7554\/elife.35082"},{"key":"57956_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach, J. et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat. Commun. 14, 8221 (2023).","journal-title":"Nat. Commun."},{"key":"57956_CR17","doi-asserted-by":"publisher","first-page":"19575","DOI":"10.1073\/pnas.0905884106","volume":"106","author":"KA Jones","year":"2009","unstructured":"Jones, K. A. et al. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc. Natl. Acad. Sci. USA 106, 19575\u201319580 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57956_CR18","doi-asserted-by":"publisher","unstructured":"Raval, N. R. et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms22020835 (2021).","DOI":"10.3390\/ijms22020835"},{"key":"57956_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A","volume":"27","author":"DL Willins","year":"1997","unstructured":"Willins, D. L., Deutch, A. Y. & Roth, B. L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27, 79\u201382 (1997).","journal-title":"Synapse"},{"key":"57956_CR20","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574\u20131588.e19 (2020).","journal-title":"Cell"},{"key":"57956_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.abl8615","volume":"375","author":"D Cao","year":"2022","unstructured":"Cao, D. et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 375, 403\u2013411 (2022).","journal-title":"Science"},{"key":"57956_CR22","first-page":"1","volume":"36","author":"DE Nichols","year":"2018","unstructured":"Nichols, D. E. Chemistry and structure-activity relationships of psychedelics. Curr. Top. Behav. Neurosci. 36, 1\u201343 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"57956_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","volume":"600","author":"C Cao","year":"2021","unstructured":"Cao, C. et al. Structure, function and pharmacology of human itch GPCRs. Nature 600, 170\u2013175 (2021).","journal-title":"Nature"},{"key":"57956_CR24","doi-asserted-by":"publisher","first-page":"eadn6354","DOI":"10.1126\/science.adn6354","volume":"384","author":"J Lyu","year":"2024","unstructured":"Lyu, J. et al. AlphaFold2 structures guide prospective ligand discovery. Science 384, eadn6354 (2024).","journal-title":"Science"},{"key":"57956_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.str.2020.04.018","volume":"28","author":"MJ Robertson","year":"2020","unstructured":"Robertson, M. J., van Zundert, G. C. P., Borrelli, K. & Skiniotis, G. GemSpot: A pipeline for robust modeling of ligands into cryo-EM maps. Structure 28, 707\u2013716.e3 (2020).","journal-title":"Structure"},{"key":"57956_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41586-021-03376-8","volume":"592","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 592, 469\u2013473 (2021).","journal-title":"Nature"},{"key":"57956_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","volume":"168","author":"D Wacker","year":"2017","unstructured":"Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377\u2013389 (2017).","journal-title":"Cell"},{"key":"57956_CR28","doi-asserted-by":"publisher","first-page":"111211","DOI":"10.1016\/j.celrep.2022.111211","volume":"40","author":"RH Gumpper","year":"2022","unstructured":"Gumpper, R. H., Fay, J. F. & Roth, B. L. Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors. Cell Rep. 40, 111211 (2022).","journal-title":"Cell Rep."},{"key":"57956_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41586-022-05258-z","volume":"610","author":"AL Kaplan","year":"2022","unstructured":"Kaplan, A. L. et al. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature 610, 582\u2013591 (2022).","journal-title":"Nature"},{"key":"57956_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/ajp.116.3.261","volume":"116","author":"WJ Turner","year":"1959","unstructured":"Turner, W. J., Almudevar, M. & Merlis, S. Chemotherapeutic trials in psychosis. III. Addendum-2-brom-d-lysergic acid diethylamide (BOL). Am. J. Psychiatry 116, 261\u2013262 (1959).","journal-title":"Am. J. Psychiatry"},{"key":"57956_CR31","doi-asserted-by":"publisher","first-page":"112203","DOI":"10.1016\/j.celrep.2023.112203","volume":"42","author":"V Lewis","year":"2023","unstructured":"Lewis, V. et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 42, 112203 (2023).","journal-title":"Cell Rep."},{"key":"57956_CR32","doi-asserted-by":"crossref","unstructured":"Cao, C. et al. Signaling snapshots of 5-HT2BR activated by theprototypical psychedelic LSD. Neuron 110, 3154\u20133167 (2022).","DOI":"10.1016\/j.neuron.2022.08.006"},{"key":"57956_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14889-7","volume":"11","author":"T Che","year":"2020","unstructured":"Che, T. et al. Nanobody-enabled monitoring of kappa opioid receptor states. Nat. Commun. 11, 1145 (2020).","journal-title":"Nat. Commun."},{"key":"57956_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41594-018-0180-z","volume":"26","author":"KT Kimura","year":"2019","unstructured":"Kimura, K. T. et al. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine. Nat. Struct. Mol. Biol. 26, 121\u2013128 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"57956_CR35","doi-asserted-by":"publisher","first-page":"18684","DOI":"10.1073\/pnas.1110499108","volume":"108","author":"RO Dror","year":"2011","unstructured":"Dror, R. O. et al. Activation mechanism of the \u03b22-adrenergic receptor. Proc. Natl. Acad. Sci. USA 108, 18684\u201318689 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57956_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41586-019-1337-6","volume":"572","author":"HE Kato","year":"2019","unstructured":"Kato, H. E. et al. Conformational transitions of a neurotensin receptor 1-Gi1 complex. Nature 572, 80\u201385 (2019).","journal-title":"Nature"},{"key":"57956_CR37","doi-asserted-by":"publisher","unstructured":"Gumpper, R. H., Fay, J. & Roth, B. L. Molecular insights into RNA editing-induced regulation of serotoninergic signaling. Cell Rep. 40, https:\/\/doi.org\/10.1016\/j.celrep.2022.111211 (2022).","DOI":"10.1016\/j.celrep.2022.111211"},{"key":"57956_CR38","doi-asserted-by":"crossref","unstructured":"Zhang, S. et al. Inactive and active state structures template selective tools for the human 5-HT5A receptor. Nat. Struct. Mol. Biol. 29, 677\u2013687 (2022).","DOI":"10.1038\/s41594-022-00796-6"},{"key":"57956_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1124\/mol.113.089649","volume":"85","author":"KL White","year":"2014","unstructured":"White, K. L. et al. Identification of novel functionally selective \u03ba-opioid receptor scaffolds. Mol. Pharmacol. 85, 83\u201390 (2014).","journal-title":"Mol. Pharmacol."},{"key":"57956_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1021\/cn200111m","volume":"3","author":"T Kenakin","year":"2012","unstructured":"Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193\u2013203 (2012).","journal-title":"ACS Chem. Neurosci."},{"key":"57956_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd3954","volume":"12","author":"T Kenakin","year":"2013","unstructured":"Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205\u2013216 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"57956_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10842","volume":"7","author":"C Klein Herenbrink","year":"2016","unstructured":"Klein Herenbrink, C. et al. The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7, 10842 (2016).","journal-title":"Nat. Commun."},{"key":"57956_CR43","doi-asserted-by":"publisher","first-page":"107702","DOI":"10.1016\/j.jsb.2021.107702","volume":"213","author":"A Punjani","year":"2021","unstructured":"Punjani, A. & Fleet, D. J. 3D variability analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. J. Struct. Biol. 213, 107702 (2021).","journal-title":"J. Struct. Biol."},{"key":"57956_CR44","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41592-023-01853-8","volume":"20","author":"A Punjani","year":"2023","unstructured":"Punjani, A. & Fleet, D. J. 3DFlex: determining structure and motion of flexible proteins from cryo-EM. Nat. Methods 20, 860\u2013870 (2023).","journal-title":"Nat. Methods"},{"key":"57956_CR45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"57956_CR46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/cmb.2022.0366","volume":"30","author":"HS Lim","year":"2023","unstructured":"Lim, H. S. & Qiu, P. Quantifying cell-type-specific differences of single-cell datasets using uniform manifold approximation and projection for dimension reduction and shapley additive exPlanations. J. Comput. Biol. 30, 738\u2013750 (2023).","journal-title":"J. Comput. Biol."},{"key":"57956_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","volume":"558","author":"A Koehl","year":"2018","unstructured":"Koehl, A. et al. Structure of the \u00b5-opioid receptor-Gi protein complex. Nature 558, 547\u2013552 (2018).","journal-title":"Nature"},{"key":"57956_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","volume":"152","author":"DN Mastronarde","year":"2005","unstructured":"Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36\u201351 (2005).","journal-title":"J. Struct. Biol."},{"key":"57956_CR49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"57956_CR50","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","volume":"17","author":"A Punjani","year":"2020","unstructured":"Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214\u20131221 (2020).","journal-title":"Nat. Methods"},{"key":"57956_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18952-1","volume":"11","author":"T Bepler","year":"2020","unstructured":"Bepler, T., Kelley, K., Noble, A. J. & Berger, B. Topaz-Denoise: general deep denoising models for cryoEM and cryoET. Nat. Commun. 11, 5208 (2020).","journal-title":"Nat. Commun."},{"key":"57956_CR52","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jmb.2003.07.013","volume":"333","author":"PB Rosenthal","year":"2003","unstructured":"Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333, 721\u2013745 (2003).","journal-title":"J. Mol. Biol."},{"key":"57956_CR53","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nmeth.2115","volume":"9","author":"SHW Scheres","year":"2012","unstructured":"Scheres, S. H. W. & Chen, S. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853\u2013854 (2012).","journal-title":"Nat. Methods"},{"key":"57956_CR54","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"57956_CR55","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1107\/S2059798318009324","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine, P. V. et al. New tools for the analysis and validation of cryo-EM maps and atomic models. Acta Crystallogr. D Struct. Biol. 74, 814\u2013840 (2018).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"57956_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci 27, 293\u2013315 (2018).","journal-title":"Protein Sci"},{"key":"57956_CR57","doi-asserted-by":"crossref","unstructured":"Sanchez-Garcia, R., Gomez-Blanco, J. & Cuervo, A. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2020).","DOI":"10.1101\/2020.06.12.148296"},{"key":"57956_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"57956_CR59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"57956_CR60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D Struct. Biol. 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"57956_CR61","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1107\/S0907444909029436","volume":"65","author":"NW Moriarty","year":"2009","unstructured":"Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. D Biol. Crystallogr. 65, 1074\u20131080 (2009).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"57956_CR62","doi-asserted-by":"crossref","unstructured":"Gowers, R. et al. Mdanalysis: A python package for the rapid analysis of molecular dynamics simulations. In Proceedings of the 15th Python in Science Conference 98\u2013105 (SciPy, 2016).","DOI":"10.25080\/Majora-629e541a-00e"},{"key":"57956_CR63","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","volume":"16","author":"RHJ Olsen","year":"2020","unstructured":"Olsen, R. H. J. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841\u2013849 (2020).","journal-title":"Nat. Chem. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57956-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57956-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57956-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T03:52:01Z","timestamp":1742442721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57956-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["57956"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-57956-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H.G is an active consultant for 2A Biosciences. B.L.R. is a member of the SAB for Onsero, Escient, Septerna, Epiodyne, and Levator. J.J. is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received or has received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc., and Cullinan Oncology, Inc. D.E.N. is a founder of 2A Biosciences. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2734"}}